Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

May 30, 2027

Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
DRUG

Molgramostim

Molgramostim 300 µg nebulizer solution

DRUG

Placebo

Matching placebo nebulizer solution

DRUG

Molgramostim Open-label

Molgramostim 300 µg nebulizer solution

Trial Locations (54)

1070

Hôpital Erasme, Brussels

2050

Royal Prince Alfred Hospital, Camperdown

2145

Westmead Hospital, Westmead

3000

UZ Leuven - Campus Gasthuisberg - Pneumologie, Leuven

6010

Health Sciences University Gulhane Training and Research Hospital, Ankara

12462

Attikon University Hospital, Athens

15213

University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania Perelman School of Medicine - Pulmonology, Philadelphia

21201

University of Maryland Medical Center, Baltimore

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

27610

Wake Med Health & Hospital, Raleigh

27710

Duke University Medical Center, Durham

30322

Emory University, Atlanta

32610

University of Florida Health, Gainesville

34020

Yedikule Chest Disease and Surgery Training and Research Hospital, Istanbul

35033

CHU Pontchaillou, Rennes

35100

Ege University Hospital - Department of Pulmonology, Bornova

44195

Cleveland Clinic, Cleveland

45239

Ruhrlandklinik Westdeutsches Lungenzentrum, Essen

60153

Loyola University, Maywood

63110

Washington University in St. Louis, St Louis

69126

Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg

69500

Hôpital Louis Pradel, Bron

72205

University Of Arkansas For Medical Services, Little Rock

75390

UT Southwestern Medical Center, Dallas

80206

National Jewish Health, Denver

82131

Asklepios Fachkliniken Muenchen-Gauting, Muenchen-Gauting

90095

UCLA David Geffen School of Medicine, Los Angeles

06520

Yale University, New Haven

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

T2N 4N1

University of Calgary, Calgary

L8N 4A6

St Joseph's Healthcare Hamilton Research, Hamilton

G1V 4G5

University Institute of Cardiology and Respirology of Quebec, Québec

DO4 T6F4

St. Vincent's University Hospital, Dublin

060-8648

Hokkaido University Hospital, Sapporo

236-0051

Kanagawa Cardiovascular and Respiratory Center, Yokohama

980-8574

Tohoku University Hospital - Respiratory Tract Medicine, Sendai

591-8555

National Hospital Organization Kinki-Chuo Chest medical Center, Sakai

181-8611

Kyorin University Hospital, Mitaka

260-8677

Chiba University Hospital - Respiratory Medicine, Chiba

860-8556

Kumamoto University Hospital, Kumamoto

480-1195

Aichi Medical University Hospital, Nagakute

330-8553

Saitama Red Cross Hospital, Saitama

3435CM

St Antonius Hospital, Nieuwegein

01-138

Instytut Gruzlicy i Chorob Pluc, Warsaw

1769-001

Hospital Pulido Valente, Lisbon

4200-319

Hospital São João, Porto

050159

"Institutul de Pneumoftiziologie Marius Nasta", Bucharest

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital - Yonsei University Health System - Pulmonary, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08907

Hospital Universitario de Bellvitge, Barcelona

SW3 6NP

Royal Brompton and Harefield NHS Foundation Trust, London

All Listed Sponsors
lead

Savara Inc.

INDUSTRY

NCT04544293 - Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Biotech Hunter | Biotech Hunter